First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
The administration of EGFRvIII × CD3 TCB in a maintenance setting, following standard of care treatment, was safe and well tolerated up to the highest tested dose of 10 mg Q3W. However, evidence of efficacy was not observed at the evaluated doses, suggesting that a study of higher dose levels may be warranted.
Authors
- María Vieito (ORCID: https://orcid.org/0000-0001-7531-343X)
- Christina Schiff
- Warren Mason (ORCID: https://orcid.org/0000-0001-9107-2242)
- Mark Rosenthal (ORCID: https://orcid.org/0000-0003-1152-6764)
- Ingo K. Mellinghoff (ORCID: https://orcid.org/0000-0002-4347-8149)
- Vincent Wolowski
- Christian Heichinger
- James Richard Whittle (ORCID: https://orcid.org/0000-0002-4740-2037)
- Kristoffer Staal Rohrberg (ORCID: https://orcid.org/0000-0002-5448-9003)
- Antje Wick (ORCID: https://orcid.org/0000-0003-0020-6386)
- Nick Flinn
- Jinhai Gou (ORCID: https://orcid.org/0000-0002-2706-8094)
- Florian Heil (ORCID: https://orcid.org/0000-0002-2056-0270)
- Andreas Roller (ORCID: https://orcid.org/0000-0001-6335-0962)
- Inja Waldhauer (ORCID: https://orcid.org/0000-0001-8008-8660)
- Sharmistha Dey (ORCID: https://orcid.org/0000-0003-4122-7415)
- Meike Schneider
- Bárbara Romagnoli
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Timothy F. Cloughesy (ORCID: https://orcid.org/0000-0002-8656-7483)
- María E. Rodríguez-Ruiz (ORCID: https://orcid.org/0000-0002-9765-2499)
- Michael Derks (ORCID: https://orcid.org/0000-0002-4918-7828)
- Eduardo Castañón
- François Prince (ORCID: https://orcid.org/0000-0002-1650-7346)
- Lance A. Smith
- Robert Chong
- Myra van Linde
- Nina Henkel
Institutions
- Roche (Switzerland) (CH)
- Hebron University (PS)
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Heidelberg University (DE)
- Peter MacCallum Cancer Centre (AU)
- Ronald Reagan UCLA Medical Center (US)
- University Hospital Heidelberg (DE)
- Copenhagen University Hospital (DK)
- Princess Margaret Cancer Centre (CA)
- Rigshospitalet (DK)
- Center for Neuro-Oncology (US)
- National Center for Tumor Diseases (DE)
- Roche (United Kingdom) (GB)
- Dana-Farber Cancer Institute (US)
- Vall d'Hebron Hospital Universitari (ES)
- Clinica Universidad de Navarra (ES)
- Amsterdam University Medical Centers (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf160
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche